Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.


Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
01 08 2022
Historique:
pubmed: 10 2 2022
medline: 3 8 2022
entrez: 9 2 2022
Statut: ppublish

Résumé

CNS germ cell tumors (GCTs) predominantly develop in pediatric and young adult patients with variable responses to surgery, radiation, and chemotherapy. This study aimed to examine the complex and largely unknown pathogenesis of CNS GCTs. We used a combined transcriptomic and methylomic approach in 84 cases and conducted an integrative analysis of the normal cells undergoing embryogenesis and testicular GCTs. Genome-wide transcriptome analysis in CNS GCTs indicated that germinoma had a transcriptomic profile representative of primitive cells during early embryogenesis with high meiosis/mitosis potentials, while nongerminomatous GCTs (NGGCTs) had differentiated phenotypes oriented toward tissue formation and organogenesis. Co-analysis with the transcriptome of human embryonic cells revealed that germinomas had expression profiles similar to those of primordial germ cells, while the expression profiles of NGGCTs were similar to those of embryonic stem cells. Some germinoma cases were characterized by extensive immune-cell infiltration and high expression of cancer-testis antigens. NGGCTs had significantly higher immune-cell infiltration, characterized by immune-suppression phenotype. CNS and testicular GCTs (TGCTs) had similar mutational profiles; TGCTs showed enhanced copy number alterations. Methylation analysis clustered germinoma/seminoma and nongerminoma/nonseminoma separately. Germinoma and seminoma were co-categorized based on the degree of the tumor microenvironment balance. These results suggested that the pathophysiology of GCTs was less dependent on their site of origin and more dependent on the state of differentiation as well as on the tumor microenvironment balance. This study revealed distinct biological properties of GCTs, which will hopefully lead to future treatment development.

Sections du résumé

BACKGROUND
CNS germ cell tumors (GCTs) predominantly develop in pediatric and young adult patients with variable responses to surgery, radiation, and chemotherapy. This study aimed to examine the complex and largely unknown pathogenesis of CNS GCTs.
METHODS
We used a combined transcriptomic and methylomic approach in 84 cases and conducted an integrative analysis of the normal cells undergoing embryogenesis and testicular GCTs.
RESULTS
Genome-wide transcriptome analysis in CNS GCTs indicated that germinoma had a transcriptomic profile representative of primitive cells during early embryogenesis with high meiosis/mitosis potentials, while nongerminomatous GCTs (NGGCTs) had differentiated phenotypes oriented toward tissue formation and organogenesis. Co-analysis with the transcriptome of human embryonic cells revealed that germinomas had expression profiles similar to those of primordial germ cells, while the expression profiles of NGGCTs were similar to those of embryonic stem cells. Some germinoma cases were characterized by extensive immune-cell infiltration and high expression of cancer-testis antigens. NGGCTs had significantly higher immune-cell infiltration, characterized by immune-suppression phenotype. CNS and testicular GCTs (TGCTs) had similar mutational profiles; TGCTs showed enhanced copy number alterations. Methylation analysis clustered germinoma/seminoma and nongerminoma/nonseminoma separately. Germinoma and seminoma were co-categorized based on the degree of the tumor microenvironment balance.
CONCLUSIONS
These results suggested that the pathophysiology of GCTs was less dependent on their site of origin and more dependent on the state of differentiation as well as on the tumor microenvironment balance. This study revealed distinct biological properties of GCTs, which will hopefully lead to future treatment development.

Identifiants

pubmed: 35137206
pii: 6524508
doi: 10.1093/neuonc/noac021
pmc: PMC9340652
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1246-1258

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Cell. 2015 Jan 15;160(1-2):253-68
pubmed: 25543152
Neurosurgery. 2020 Sep 1;87(3):563-572
pubmed: 32348488
J Neurosurg. 1997 Mar;86(3):446-55
pubmed: 9046301
Proc Natl Acad Sci U S A. 1954 Nov;40(11):1080-7
pubmed: 16578442
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
BMC Cancer. 2015 Oct 23;15:769
pubmed: 26497383
Cell. 2015 Jun 4;161(6):1425-36
pubmed: 26004067
Nat Struct Mol Biol. 2013 Sep;20(9):1131-9
pubmed: 23934149
Acta Pathol Microbiol Scand. 1965;64(4):407-29
pubmed: 5318716
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
Cancer. 2011 Dec 1;117(23):5402-11
pubmed: 21563173
Cell. 2015 Jun 4;161(6):1437-52
pubmed: 26046443
BMC Genomics. 2010 Feb 24;11:132
pubmed: 20178649
Neurooncol Adv. 2021 Aug 10;3(1):vdab110
pubmed: 34549182
Acta Neuropathol. 2017 Mar;133(3):445-462
pubmed: 28078450
Curr Opin Genet Dev. 2003 Oct;13(5):463-71
pubmed: 14550410
Neurol Res. 1989 Jun;11(2):118-26
pubmed: 2569683
Cell. 2015 Jun 4;161(6):1453-67
pubmed: 26046444
Neuro Oncol. 2001 Jul;3(3):174-83
pubmed: 11465398
Int J Androl. 2007 Aug;30(4):256-63; discussion 263-4
pubmed: 17705807
Neuropathol Appl Neurobiol. 2020 Feb;46(2):111-124
pubmed: 31179566
Nature. 2014 Jul 10;511(7508):241-5
pubmed: 24896186
Acta Neuropathol. 2016 Jun;131(6):889-901
pubmed: 26956871
Cell Stem Cell. 2015 Aug 6;17(2):178-94
pubmed: 26189426
Neuro Oncol. 2019 Dec 17;21(12):1565-1577
pubmed: 31420671

Auteurs

Hirokazu Takami (H)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

Asmaa Elzawahry (A)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Yasin Mamatjan (Y)

MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Faculty of Science, Thompson Rivers University, Kamloops, British Columbia, Canada.

Shintaro Fukushima (S)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.

Kohei Fukuoka (K)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Division of Pediatric Neuro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Department of Pediatrics, Saitama Children's Medical Center, Saitama, Japan.

Tomonari Suzuki (T)

Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan.

Takaaki Yanagisawa (T)

Division of Pediatric Neuro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

Yuko Matsushita (Y)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan.

Taishi Nakamura (T)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan.

Kaishi Satomi (K)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

Shota Tanaka (S)

Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

Akitake Mukasa (A)

Department of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.

Nobuhito Saito (N)

Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

Masayuki Kanamori (M)

Department of Neurosurgery, Tohoku University School of Medicine, Miyagi, Japan.

Toshihiro Kumabe (T)

Department of Neurosurgery, Tohoku University School of Medicine, Miyagi, Japan.
Department of Neurosurgery, Kitasato University, Kanagawa, Japan.

Teiji Tominaga (T)

Department of Neurosurgery, Tohoku University School of Medicine, Miyagi, Japan.

Keiichi Kobayashi (K)

Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan.

Motoo Nagane (M)

Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan.

Toshihiko Iuchi (T)

Department of Neurosurgery, Chiba Cancer Center, Chiba, Japan.

Kaoru Tamura (K)

Department of Neurosurgery, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Tokyo, Japan.

Taketoshi Maehara (T)

Department of Neurosurgery, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Tokyo, Japan.

Kazuhiko Sugiyama (K)

Department of Neurosurgery, Hiroshima University Faculty of Medicine, Hiroshima, Japan.

Koji Yoshimoto (K)

Department of Neurosurgery, Kyushu University Hospital, Fukuoka, Japan.
Department of Neurosurgery, Kagoshima University Hospital, Kagoshima, Japan.

Keiichi Sakai (K)

Department of Neurosurgery, Shinshu Ueda Medical Center, Ueda, Japan.

Masahiro Nonaka (M)

Department of Neurosurgery, Kansai Medical University, Osaka, Japan.

Akio Asai (A)

Department of Neurosurgery, Kansai Medical University, Osaka, Japan.

Kiyotaka Yokogami (K)

Department of Neurosurgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.

Hideo Takeshima (H)

Department of Neurosurgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.

Yoshitaka Narita (Y)

Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan.

Soichiro Shibui (S)

Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan.

Yoichi Nakazato (Y)

Department of Pathology, Hidaka Hospital, Gunma, Japan.

Natsuko Hama (N)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Yasushi Totoki (Y)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Mamoru Kato (M)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Tatsuhiro Shibata (T)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Ryo Nishikawa (R)

Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan.

Masao Matsutani (M)

Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan.

Koichi Ichimura (K)

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Department of Brain Disease Translational Research, Juntendo University Faculty of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH